AIM To evaluate the suitability evaluation of camrelizumab by investigating the cognition of medical staff on the safety of camrelizumab.METHODS From April to September of 2023,electronic questionnaires were distributed to oncological doctors,nurses,and pharmacists from more than 10 cities in Hubei Province using non-probabilistic purposeful sampling.It mainly focused on the 3 aspects of health care workers'cognition and evaluation:the cognitive status of security information in the package insert for camrelizumab,concerns about immune-related adverse events(irAEs),and safety of reactive cutaneous capillary endothelial proliferation(RCCEP).RESULTS A total of 204 questionnaires were collected,with an effective recovery rate of 68.0％.The average score of respondents'recognition of the safety information provided by the package insert was(3.78±0.69).Statistically significant differences in the scores of agreement with the safety information were observed among medical staff with different frequencies of obtaining safety information about camrelizumab(P＜0.05).RCCEP was the most concerning irAE among medical staff(57.35％).Medical staff were particularly concerned about the impact of complications on medication safety(67.16％),the progress of normal antitumor treatment(54.90％),and the psychological fear affecting medication adherence(40.69％).Medical staff expected to obtain more information on the prevention methods of RCCEP(59.8％),the treatment and nursing methods of RCCEP(59.31％),the risk factors and high-risk population screening methods of RCCEP(55.39％).CONCLUSION The overall level of awareness regarding the safey of camrelizumab among medical staff is relatively low.Medical staff may strengthen the access to drug safety information of camrelizumab to further ensure the safety of clinical medication.
维普
万方数据